- Lobbying
- Beth AND Roberts
Lobbying Arrangements Results for 'Beth Roberts'
Former Covered Federal Workers:
Other Lobbyists:
Issue | Client | Firm | Lobbyists | Start Date | Latest Filing Date |
---|---|---|---|---|---|
Details H.R. 2356 and S.2363, the Better Wound Care at Home Act |
Smith and Nephew Inc
|
Hogan Lovells US LLP | |||
Details CMS reimbursement issue. |
Intersect ENT
|
Hogan Lovells US LLP | |||
Details Medicare coverage |
VitalWear Inc
|
Hogan Lovells US LLP | |||
Details Research funding in the FY 2009 Labor, HHS Appropriations bill |
Nabi Biopharmaceuticals
|
HOGAN & HARTSON LLP | |||
Details Medicare coverage and reimbursement |
Heartware Inc
|
Hogan Lovells US LLP | |||
Details CMS reimbursement issues. |
Accuray Incorporated
|
Hogan Lovells US LLP | |||
Details 340B Drug Discount Program - Program Implementation Oversight. Reimbursement for Innovative Products. 340B Drug Discount Program - Program Implementation Oversight. Reimbursement for Innovative Pro... |
BIOTECHNOLOGY INDUSTRY ORGANIZATION
|
Hogan Lovells US LLP | |||
Details CMS reimbursement issues. |
Cochlear Americas
|
Hogan Lovells US LLP | |||
Details FDA drug approval |
Vical Inc
|
Hogan Lovells US LLP | |||
Details Health reform. Appropriations; Food and Blood Safety; cancer research funding. |
Gen-Probe Incorporated
|
Hogan Lovells f/k/a Hogan & Hartson LLP | |||
Details Medicare coverage and reimbursement |
TAP Pharmaceuticals, Inc.
|
HOGAN & HARTSON LLP | |||
Details Lobbying on general eye health issues and CMS reimbursement issues. |
EyePoint Pharmaceuticals, Inc
|
Hogan Lovells US LLP | |||
Details Least costly alternative policies |
Takeda Pharmaceutical Company, Limited
|
HOGAN & HARTSON LLP | |||
Details Medicare. |
Sanofi US Services Inc f/k/a sanofi-aventis U.S. Inc.
|
Hogan Lovells US LLP | |||
Details Medicare coverage and reimbursement |
Association of Community Cancer Centers
|
Hogan Lovells US LLP | |||
Details Reimbursement issues regarding anti-infective products |
Cormedix
|
Hogan Lovells US LLP | |||
Details Least costly alternative policies |
Abbott Laboratories
Global health care company devoted to discovering new meds, new tech.& new health mgmt. |
HOGAN & HARTSON LLP | |||
Details Preventing Department of Justice from interfering into State medical cannabis programs Allowing the VA to recommend medical cannabis as a treatment option Making access to medical cannabis legal |
AMERICANS FOR SAFE ACCESS
|
in-house lobbying | |||
Details Draft legislation related to Section 404 of the Clean Water Act and changes to nationwide permits; HR 6129 Studying NEPA's Impact on Projects Act; S 1863 PROVE IT Act of 2023; S 3496 Orphan Well Gr... |
American Petroleum Institute
|
in-house lobbying |